Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
Rivogenlecleucel (BPX-501) comprises allogeneic T-cells transduced with a vector encoding inducible Casp9 that is linked to a drug binding domain, which enables induction of Casp9 with AP1903 if GVHD develops, resulting increased Casp9 expression and induction of T-cell death (PMID: 29343836).
|CAS Registry Number||NA|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Rimiducid + Rivogenlecleucel||Rimiducid Rivogenlecleucel||0||2|